Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM08CG7)

• Drug Name: 4-[2-(2-Benzyl-phenoxy)-ethyl]-morpholine Drug Info
• Synonyms: CHEMBL365697; 4-[2-(2-benzylphenoxy)ethyl]morpholine; AC1MGXJ0; 4-[2-(2-Benzyl-phenoxy)-ethyl]-morpholine; BDBM50151042

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 2993172
  TTD Drug ID: DM08CG7

Molecule-Related Drug Atlas

Drug(s) Targeting Dopamine D1 receptor (D1R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Phenyltoloxamine	DMKAEQW	Allergy	4A80-4A85	Approved	[1]
Pergolide	DM14MAE	Parkinson disease	8A00.0	Approved	[2]
Methylergonovine	DMBEX4O	Spontaneous abortion	JA00.0	Approved	[3]
Fenoldopam	DMFAOKP	Hypertension	BA00-BA04	Approved	[4]
Zicronapine	DMP8ESD	Schizophrenia	6A20	Phase 3	[5]
Ecopipam	DMS9R43	Cocaine addiction	6C45.2	Phase 3	[6]
DAS-431	DMM3BPL	Dementia	6D80-6D86	Phase 2	[7]
Dihydrexidine	DMACPQO	Psychotic disorder	6A20-6A25	Phase 1/2	[8]
Lu AF28996	DMY572G	Parkinson disease	8A00.0	Phase 1	[9]
BAM-1110	DMPMKUF	Parkinson disease	8A00.0	Discontinued in Phase 2	[10]

Drug(s) Targeting Dopamine D4 receptor (D4R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[2]
Phenyltoloxamine	DMKAEQW	Allergy	4A80-4A85	Approved	[1]
CM-2395	DMASPWR	Schizophrenia	6A20	Phase 3	[11]
RP5063	DMKUE8O	Schizophrenia	6A20	Phase 2	[12]
L-745,870	DMTGR25	Psychotic disorder	6A20-6A25	Phase 2	[13]
NGD 94-1	DMM1Y8F	Schizophrenia	6A20	Phase 1	[14]
ABT-724	DMDQVY4	Erectile dysfunction	HA01.1	Discontinued in Phase 2	[15]
Lu-35138	DMQ7A35	Psychotic disorder	6A20-6A25	Discontinued in Phase 2	[16]
NGD-94-4	DMZ9WLO	Schizophrenia	6A20	Discontinued in Phase 1	[17]
PD-165167	DMD0GB4	Schizophrenia	6A20	Preclinical	[14]

Drug(s) Targeting Dopamine D5 receptor (D5R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Phenyltoloxamine	DMKAEQW	Allergy	4A80-4A85	Approved	[1]
LE-300	DMGJL16	Schizophrenia	6A20	Preclinical	[14]
ZD-3638	DM6M9GC	Schizophrenia	6A20	Terminated	[14]
GMC-283	DMT1RH6	Schizophrenia	6A20	Terminated	[14]
(+/-)-nantenine	DM0L3GE	Discovery agent	N.A.	Investigative	[18]
ISOCLOZAPINE	DM52CPU	Discovery agent	N.A.	Investigative	[19]
FLUMEZAPINE	DMW0HOG	Discovery agent	N.A.	Investigative	[20]
ISOLOXAPINE	DMH1BN4	Discovery agent	N.A.	Investigative	[21]
1-Dibenzo[b,f]oxepin-10-yl-4-methyl-piperazine	DMOL2Y0	Discovery agent	N.A.	Investigative	[19]
1-[3-(2-Benzyl-phenoxy)-propyl]-pyrrolidine	DMD2NXL	Discovery agent	N.A.	Investigative	[1]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dopamine D1 receptor (D1R)	TTZFYLI	DRD1_HUMAN	Inhibitor	[1]
Dopamine D4 receptor (D4R)	TTE0A2F	DRD4_HUMAN	Inhibitor	[1]
Dopamine D5 receptor (D5R)	TTS2PH3	DRD5_HUMAN	Inhibitor	[1]

References

• [1] Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8.
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [3] Reinforcement in an in vitro analog of appetitive classical conditioning of feeding behavior in Aplysia: blockade by a dopamine antagonist. Learn Mem. 2005 May-Jun;12(3):216-20.
• [4] Etiology of iodinated radiocontrast nephrotoxicity and its attenuation by beraprost. Yakugaku Zasshi. 2008 Jul;128(7):1023-9.
• [5] Clinical pipeline report, company report or official report of Lundbeck.
• [6] A D1 receptor antagonist, ecopipam, for treatment of tics in Tourette syndrome.Clin Neuropharmacol.2014 Jan-Feb;37(1):26-30.
• [7] Adrogolide HCl (ABT-431; DAS-431), a prodrug of the dopamine D1 receptor agonist, A-86929: preclinical pharmacology and clinical data. CNS Drug Rev. 2001 Fall;7(3):305-16.
• [8] trans-2,3-dihydroxy-6a,7,8,12b-tetrahydro-6H-chromeno[3,4-c]isoquinoline: synthesis, resolution, and preliminary pharmacological characterization o... J Med Chem. 2006 Nov 16;49(23):6848-57.
• [9] Clinical pipeline report, company report or official report of Lundbeck
• [10] Therapeutic effects of dopamine D1/D2 receptor agonists on detrusor hyperreflexia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinso... J Pharmacol Exp Ther. 1998 Jul;286(1):228-33.
• [11] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127)
• [12] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [13] Dopamine D4 receptor involvement in the discriminative stimulus effects in rats of LSD, but not the phenethylamine hallucinogen DOI. Psychopharmacology (Berl). 2009 Apr;203(2):265-77.
• [14] The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
• [15] Activation of dopamine D4 receptors by ABT-724 induces penile erection in rats. Proc Natl Acad Sci U S A. 2004 April 27; 101(17): 6758-6763.
• [16] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014237)
• [17] I. NGD 94-1: identification of a novel, high-affinity antagonist at the human dopamine D4 receptor. J Pharmacol Exp Ther. 1997 Aug;282(2):1011-9.
• [18] Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31.
• [19] Affinity of 10-(4-methylpiperazino)dibenz[b,f]oxepins for clozapine and spiroperidol binding sites in rat brain. J Med Chem. 1982 Jul;25(7):855-8.
• [20] Effects of conformationally restricted 4-piperazinyl-10H-thienobenzodiazepine neuroleptics on central dopaminergic and cholinergic systems. J Med Chem. 1982 Oct;25(10):1133-40.
• [21] Synthesis of clozapine analogues and their affinity for clozapine and spiroperidol binding sites in rat brain. J Med Chem. 1981 Sep;24(9):1021-6.